Biologics The Key to Next Generation Dermatology RD
White Paper
Feb 01, 2019

Dermatologic conditions, including hair, skin and nail disorders, are estimated to impact one-third of the global population. Drug developers are taking note; the global commercial dermatology market is estimated to reach $33.7 billion by 2022, rising at a 7.73 percent CAGR from 2015 to 2022.1 Historically, dermatology treatment options could largely be classified as topical, phototherapy, or conventional drugs delivered systemically. More recently, research has led to exploration of another treatment option: biologics.

The emergence of biologic therapies for dermatologic conditions created a paradigm shift for patients, physicians and sponsors. Typically offered as a secondor third-line therapy, biologics offer treatment options for patients often with the most severe or debilitating presentations of dermatologic conditions. These options are increasing; a May 2016 report from GBI estimates 37 percent of the approximately 800 dermatology products in development are biologic agents.

This white paper will explore the evolution of biologics within the dermatology landscape, with an emphasis on clinical trial considerations and best practices for sponsors developing biologic agents.

Biologics, derived from living organisms, have been in use for decades (e.g., insulin or vaccines derived from eggs). Today’s biologics – those developed in the past 15 years – are protein-based drugs created from genetically modified cells. Biologic agents can target more specific areas of the immune system than the “small molecule” systemic drugs that tend to impact the body’s overall immunity.


You may also be interested in
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.